Synthesis, docking and biological evaluation of oxamide and fumaramide analogs as potential AChE and BuChE inhibitors

Medicinal Chemistry Research

Volumn 24, Issue 2, 2015, Pages 588-602

  Yerdelen, Kadir Ozden ^a   Tosun, Edip ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

AChE; BuChE; Fumaramide; Molecular docking; Oxamide

Indexed keywords

EID: 84924364820     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-014-1152-4     Document Type: Article

References (37)

1. Akasofu S, Kimura M, Kosasa I, Sawada K, Ogura H (2008) Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact 175:222-226
2. Basiri A, Murugaiyaha V, Osman H, Kumar RS, Kia Y, Awang KB, Ali MA (2013) An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study. Eur J Med Chem 67:221-229
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3:186-191
4. Bullock R, Lane R (2007) Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 4:277-293
5. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimer's Dis 15:223-240
6. Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131-138
7. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42:2768-2773
8. Dumas JA, Newhouse PA (2011) The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav 99:254-261
9. Ellman GL, Courtney D, Andies V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
10. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu QS, Mamczarz J, Holloway HW, Giordano T, Chen D, Furukawa K, Sambamurti K, Brossi A, Lahiri DK (2005) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci 102:17213-17218
11. Hasan A, Khan KM, Sher M, Maharvi GM, Nawaz SA, Choudhary MI, Rahman AU, Supuran CT (2005) Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones. J Enzyme Inhib Med Chem 20:41-47
12. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT (2004) Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci 1012:153-163
13. Huang W, Lv D, Yu H, Sheng R, Kim SC, Wu P, Luo K, Li J, Hu Y (2010) Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease. Bioorg Med Chem 18:5610-5615
14. Jhee SS, Shiovitz T, Hartman RD, Messina J, Anand R, Sramek J, Cutler NR (2002) Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin Neuropharmacol 25:122-123
15. Joseph R, Ramanujam B, Acharya A, Khutia A, Rao CP (2008) Experimental and computational studies of selective recognition of Hg2+ by amide linked lower rim 1,3-dibenzimidazole derivative of calix[4]arene: species characterization in solution and that in the isolated complex, including the delineation of the nanostructures. J Org Chem 73:5745-5758
16. Kamal MA, Qu X, Yu QS, Tweedie D, Holloway HW, Li Y, Tan Y, Greig NH (2008) Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm 115:889-898
17. Khoobi M, Alipour M, Moradi A, Sakhteman A, Nadri H, Razavi SF, Ghandi M, Foroumadi A, Shafiee A (2013) Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3′,4′:5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase. Eur J Med Chem 68:291-300
18. Lambert J, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Sleegers K, Hiltunen M (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41:1094-1099
19. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, Tanzi RE, Rogers JT, Huang X (2006) Metal exposure and Alzheimer's pathogenesis. J Struct Biol 155:45-51
20. Mesulam MM, Guillozet A, Show P, Levey A, Duysen EGM, Lockridge O (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627-639
21. Musileka K, Komloova M, Holas O, Hrabinova M, Pohanka M, Dohnal V, Nachone F, Dolezal M, Kucaa K (2011) Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage e Implications for early Myasthenia gravis treatment. Eur J Med Chem 46:811-818
22. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43:436-441
23. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI (2002) Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J Biol Chem 277:40302-40308
24. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recanatini M (2003) Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J Med Chem 46:2279-2282
25. Ritchie CW, Bush A, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny RA, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685-1691
26. Samadi A, Estrada M, Pérez C, Rodríguez-Franco M, Iriepac I, Moraledac I, Chioua M, Marco-Contelles J (2012) Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling. Eur J Med Chem 57:296-301
27. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, DeStefano AL, Gudnason V, Boada M (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. J Am Med Assoc 303:1832-1840
28. Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D (2013) Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 70:165-188
29. Skrzypek A, Matysiak J, Niewiadomy A, Bajda M, Szymanski P (2013) Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors. Eur J Med Chem 62:311-319
30. Smith CP, Bores GM, Petko W, Li M, Selk DE, Rush DK, Camacho F, Winslow JT, Fishkin R, Cunningham DM, Brooks KM, Roehr J, Hartman HB, Davis L, Vargas HM (1997) Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther 280:710-720
31. Sugimoto H (2008) The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chem Biol Interact 175:204-208
32. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman B (2012) The synaptic accumulation of hyperphosphorylated tauoligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181:1426-1435
33. Xinga W, Fub Y, Shi Z, Lua D, Zhang H, Hua Y (2013) Discovery of novel 2,6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors. Eur J Med Chem 63:95-103
34. Yan H, Yao PF, Chen SB, Huang ZH, Huang SL, Tan JH, Li D, Gu LQ, Huang ZS (2013) Synthesis and evaluation of 7,8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem 63:299-312
35. Yerdelen KO (2012) Solvent-free solid supported and phase transferred catalyzed synthesis of benzaniline derivatives using microwave irradiatIon. Int J Pharm Sci Res 3(1):126-129
36. Yerdelen KO, Gul HI (2013) Synthesis and anticholinesterase activity of fumaramide derivatives. Med Chem Res 22:4920-4929
37. Zatta P, Drago D, Bolognin S, Sensi SL (2009) Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 30:346-355